Xiayu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiayu Li has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Jian Ma
Hunan Key Laboratory of Nonresolving Inflammation and Cancer, The Third Xiangya Hospital of Central South University, Changsha, China
5 shared publicationsLibin Chen
Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China
5 shared publicationsShourong Shen
Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China
4 shared publicationsBo Xiang
Hunan Key Laboratory of Nonresolving Inflammation and Cancer, The Third Xiangya Hospital of Central South University, Changsha, China
3 shared publications- Bo Xiang
NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
3 shared publications Feiyan Ai
Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China
3 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 26815
TNF-α-responsive YAP1 promotes CCL20 expression in colorectal inflammation and cancer
- 10 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 26815
Open AccessTNF-α-responsive YAP1 promotes CCL20 expression in colorectal inflammation and cancer
- 4 June 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 129
ACY-1215 ameliorates experimental colitis by inhibiting dendritic cell maturation and Th1/Th17 responses
Objective To evaluate the therapeutic potential of ACY-1215, a selective histone deacetylase 6 inhibitor, in inflammatory bowel disease and to provide mechanistic insights into its effects on dendritic cell-driven T-cell responses. Methods A dextran sulfate sodium-induced murine colitis model was used to assess the effects of ACY-1215 on disease severity, colon injury, epithelial barrier integrity, and tight junction protein expression. Bulk transcriptomic profiling of colonic tissues was performed to identify altered immune pathways. A public single-cell RNA-seq dataset, GSE134809, was reanalyzed to obtain cell-type-resolved evidence. Functional assays were conducted to examine the effects of ACY-1215 on dendritic cell maturation, migration, and dendritic cell-mediated Th1/Th17 polarization. Results ACY-1215 markedly alleviated DSS-induced colitis, as shown by reduced body weight loss, ameliorated colon shortening, attenuated histopathological injury, and restoration of tight junction protein expression. Bulk transcriptomic analysis indicated suppression of antigen-presentation programs, including reduced MHC-II-related signatures, following ACY-1215 treatment. Single-cell RNA-seq analysis implicated increased dendritic cell–T cell communication together with elevated Th1/Th17 immune programs in inflamed intestine. Consistently, ACY-1215 inhibited dendritic cell maturation and migration and consequently attenuated Th1 and Th17 polarization. Conclusions These findings support selective HDAC6 inhibition as an immunoepigenetic strategy that restrains dendritic cell-driven T-cell responses and promotes mucosal homeostasis, highlighting ACY-1215 as a mechanism-based therapeutic candidate for inflammatory bowel disease.
- 4 June 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 129
ACY-1215 ameliorates experimental colitis by inhibiting dendritic cell maturation and Th1/Th17 responses
Objective To evaluate the therapeutic potential of ACY-1215, a selective histone deacetylase 6 inhibitor, in inflammatory bowel disease and to provide mechanistic insights into its effects on dendritic cell-driven T-cell responses. Methods A dextran sulfate sodium-induced murine colitis model was used to assess the effects of ACY-1215 on disease severity, colon injury, epithelial barrier integrity, and tight junction protein expression. Bulk transcriptomic profiling of colonic tissues was performed to identify altered immune pathways. A public single-cell RNA-seq dataset, GSE134809, was reanalyzed to obtain cell-type-resolved evidence. Functional assays were conducted to examine the effects of ACY-1215 on dendritic cell maturation, migration, and dendritic cell-mediated Th1/Th17 polarization. Results ACY-1215 markedly alleviated DSS-induced colitis, as shown by reduced body weight loss, ameliorated colon shortening, attenuated histopathological injury, and restoration of tight junction protein expression. Bulk transcriptomic analysis indicated suppression of antigen-presentation programs, including reduced MHC-II-related signatures, following ACY-1215 treatment. Single-cell RNA-seq analysis implicated increased dendritic cell–T cell communication together with elevated Th1/Th17 immune programs in inflamed intestine. Consistently, ACY-1215 inhibited dendritic cell maturation and migration and consequently attenuated Th1 and Th17 polarization. Conclusions These findings support selective HDAC6 inhibition as an immunoepigenetic strategy that restrains dendritic cell-driven T-cell responses and promotes mucosal homeostasis, highlighting ACY-1215 as a mechanism-based therapeutic candidate for inflammatory bowel disease.
- Open Access
- 18 February 2025
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 40 (1) , 1-17
Dissecting the rising tide of inflammatory bowel disease among youth in a changing world: insights from GBD 2021
Objectives This study investigates the alarming epidemiological trends of inflammatory bowel disease (IBD) among children and young adults, highlighting the associated disease burden on global health. Materials and methods Utilizing data from the Global Burden of Disease (GBD) study 2021, we conducted a comprehensive analysis of age-standardized incidence rates (ASIR), age-standardized mortality rates (ASMR), disability-adjusted life years (DALYs), and estimated annual percentage changes (EAPC). Future trends were forecasted using the Bayesian age-period-cohort model. Results From 1990 to 2021, IBD incidence and DALY rates remained persistently high, with a concerning upward trend noted among children and young adults. While men experienced a decline in DALY rates, women faced increasing burdens. In 2021, high-income regions, particularly North America, reported the highest incidence and DALY rates, contrasting sharply with Central Latin America, which exhibited the lowest ASIR. Southeast Asia presented the most favorable DALY rates. A notable negative correlation was identified between DALY rates and socio-demographic index (SDI) at the national level, with high and high-middle SDI countries continuing to bear a substantial burden, while low and middle SDI nations faced rising challenges. Conclusions The persistent high burden of IBD in children and young adults signifies a critical public health concern. The marked geographical and gender disparities underscore the urgent need for tailored regional and population-based strategies aimed at primary prevention and effective management. This study illuminates the pressing necessity for policy interventions to address the growing epidemic of IBD among vulnerable populations.
- 18 February 2025
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 40 (1) , 1-17
Open AccessDissecting the rising tide of inflammatory bowel disease among youth in a changing world: insights from GBD 2021
Objectives This study investigates the alarming epidemiological trends of inflammatory bowel disease (IBD) among children and young adults, highlighting the associated disease burden on global health. Materials and methods Utilizing data from the Global Burden of Disease (GBD) study 2021, we conducted a comprehensive analysis of age-standardized incidence rates (ASIR), age-standardized mortality rates (ASMR), disability-adjusted life years (DALYs), and estimated annual percentage changes (EAPC). Future trends were forecasted using the Bayesian age-period-cohort model. Results From 1990 to 2021, IBD incidence and DALY rates remained persistently high, with a concerning upward trend noted among children and young adults. While men experienced a decline in DALY rates, women faced increasing burdens. In 2021, high-income regions, particularly North America, reported the highest incidence and DALY rates, contrasting sharply with Central Latin America, which exhibited the lowest ASIR. Southeast Asia presented the most favorable DALY rates. A notable negative correlation was identified between DALY rates and socio-demographic index (SDI) at the national level, with high and high-middle SDI countries continuing to bear a substantial burden, while low and middle SDI nations faced rising challenges. Conclusions The persistent high burden of IBD in children and young adults signifies a critical public health concern. The marked geographical and gender disparities underscore the urgent need for tailored regional and population-based strategies aimed at primary prevention and effective management. This study illuminates the pressing necessity for policy interventions to address the growing epidemic of IBD among vulnerable populations.
- Open Access
- 28 August 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (16)
Analysis of neutrophil extracellular trap‐related genes in Crohn's disease based on bioinformatics
Crohn's disease (CD) presents with diverse clinical phenotypes due to persistent inflammation of the gastrointestinal tract. Its global incidence is on the rise. Neutrophil extracellular traps (NETs) are networks released by neutrophils that capture microbicidal proteins and oxidases targeting pathogens. Research has shown that NETs are implicated in the pathogenesis of several immune‐mediated diseases such as rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. The goal of this study was to identify a panel of NET‐related genes to construct a diagnostic and therapeutic model for CD. Through analysis of the GEO database, we identified 1950 differentially expressed genes (DEGs) associated with CD. Gene enrichment and immune cell infiltration analyses indicate that neutrophil infiltrates and chemokine‐related pathways are predominantly involved in CD, with other immune cells such as CD4 and M1 macrophages also playing a role in disease progression. Utilizing weighted gene co‐expression network analysis (WGCNA) and protein–protein interaction (PPI) networks, we identified six hub genes (SPP1, SOCS3, TIMP1, IRF1, CXCL2 and CD274). To validate the accuracy of our model, we performed external validation with statistical differences(p < 0.05). Additionally, immunohistochemical experiments demonstrated higher protein expression of the hub genes in colonic tissues from CD patients compared to healthy subjects (p < 0.05). In summary, we identified six effective hub genes associated with NETs as potential diagnostic markers for CD. These markers not only offer targets for future research but also hold promise for the development of novel therapeutic interventions for CD.
- 28 August 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (16)
Open AccessAnalysis of neutrophil extracellular trap‐related genes in Crohn's disease based on bioinformatics
Crohn's disease (CD) presents with diverse clinical phenotypes due to persistent inflammation of the gastrointestinal tract. Its global incidence is on the rise. Neutrophil extracellular traps (NETs) are networks released by neutrophils that capture microbicidal proteins and oxidases targeting pathogens. Research has shown that NETs are implicated in the pathogenesis of several immune‐mediated diseases such as rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. The goal of this study was to identify a panel of NET‐related genes to construct a diagnostic and therapeutic model for CD. Through analysis of the GEO database, we identified 1950 differentially expressed genes (DEGs) associated with CD. Gene enrichment and immune cell infiltration analyses indicate that neutrophil infiltrates and chemokine‐related pathways are predominantly involved in CD, with other immune cells such as CD4 and M1 macrophages also playing a role in disease progression. Utilizing weighted gene co‐expression network analysis (WGCNA) and protein–protein interaction (PPI) networks, we identified six hub genes (SPP1, SOCS3, TIMP1, IRF1, CXCL2 and CD274). To validate the accuracy of our model, we performed external validation with statistical differences(p < 0.05). Additionally, immunohistochemical experiments demonstrated higher protein expression of the hub genes in colonic tissues from CD patients compared to healthy subjects (p < 0.05). In summary, we identified six effective hub genes associated with NETs as potential diagnostic markers for CD. These markers not only offer targets for future research but also hold promise for the development of novel therapeutic interventions for CD.
- 30 July 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1879 (5) , 189162
T cell exhaustion in human cancers
- 30 July 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1879 (5) , 189162
T cell exhaustion in human cancers
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (11) , 3452-3465
S100A8-Mediated Inflammatory Signaling Drives Colorectal Cancer Progression via the CXCL5/CXCR2 Axis
Background: S100A8/S100A9 belong to the S100 calcium-binding protein family and play an essential role in the progression of chronic inflammation in diseases. It also regulates various biological processes such as tumor cell survival, apoptosis, and invasive metastasis. The extracellular form of S100A8/S100A9 functions by modulating cellular oxidative metabolism and facilitating inflammation-to-cancer progression. This modulation occurs through specific binding to receptors like RAGE and TLR4 and activation of signaling pathways including STAT3 and NF-κB. In tumor cells, S100A8 and S100A9 induce phenotypic changes by influencing calcium ion concentrations and other pathways. However, the precise function of high S100A8/S100A9 expression in colorectal cancer cells remains unclear.
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (11) , 3452-3465
Open AccessS100A8-Mediated Inflammatory Signaling Drives Colorectal Cancer Progression via the CXCL5/CXCR2 Axis
Background: S100A8/S100A9 belong to the S100 calcium-binding protein family and play an essential role in the progression of chronic inflammation in diseases. It also regulates various biological processes such as tumor cell survival, apoptosis, and invasive metastasis. The extracellular form of S100A8/S100A9 functions by modulating cellular oxidative metabolism and facilitating inflammation-to-cancer progression. This modulation occurs through specific binding to receptors like RAGE and TLR4 and activation of signaling pathways including STAT3 and NF-κB. In tumor cells, S100A8 and S100A9 induce phenotypic changes by influencing calcium ion concentrations and other pathways. However, the precise function of high S100A8/S100A9 expression in colorectal cancer cells remains unclear.
- Open Access
- 15 June 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1204033
YAP at the progression of inflammation
Yes-associated protein (YAP) is a transcriptional regulator that affects cell proliferation, organ size and tissue development and regeneration, and has therefore, been an important object of study. In recent years, there has been an increasing research focus on YAP in inflammation and immunology, and the role of YAP in the development of inflammation and in immune escape by tumors has been progressively elucidated. Because YAP signaling involves a variety of different signal transduction cascades, the full range of functions in diverse cells and microenvironments remains incompletely understood. In this article, we discuss the complex involvement of YAP in inflammation, the molecular mechanisms through which it exercises pro- and anti-inflammatory effects under different conditions, and the progress achieved in elucidating the functions of YAP in inflammatory diseases. A thorough understanding of YAP signaling in inflammation will provide a foundation for its use as a therapeutic target in inflammatory diseases.
- 15 June 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1204033
Open AccessYAP at the progression of inflammation
Yes-associated protein (YAP) is a transcriptional regulator that affects cell proliferation, organ size and tissue development and regeneration, and has therefore, been an important object of study. In recent years, there has been an increasing research focus on YAP in inflammation and immunology, and the role of YAP in the development of inflammation and in immune escape by tumors has been progressively elucidated. Because YAP signaling involves a variety of different signal transduction cascades, the full range of functions in diverse cells and microenvironments remains incompletely understood. In this article, we discuss the complex involvement of YAP in inflammation, the molecular mechanisms through which it exercises pro- and anti-inflammatory effects under different conditions, and the progress achieved in elucidating the functions of YAP in inflammatory diseases. A thorough understanding of YAP signaling in inflammation will provide a foundation for its use as a therapeutic target in inflammatory diseases.
- 2 November 2021
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 78 (23) , 7915
Correction to: TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development
- 2 November 2021
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 78 (23) , 7915
Correction to: TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development
- Open Access
- 23 May 2020
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 77 (21) , 4325-4346
TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development
Squamous cell carcinoma (SCC) is an aggressive malignancy that can originate from various organs. TP63 is a master regulator that plays an essential role in epidermal differentiation. It is also a lineage-dependent oncogene in SCC. ΔNp63α is the prominent isoform of TP63 expressed in epidermal cells and SCC, and overexpression promotes SCC development through a variety of mechanisms. Recently, ΔNp63α was highlighted to act as an epidermal-specific pioneer factor that binds closed chromatin and enhances chromatin accessibility at epidermal enhancers. ΔNp63α coordinates chromatin-remodeling enzymes to orchestrate the tissue-specific enhancer landscape and three-dimensional high-order architecture of chromatin. Moreover, ΔNp63α establishes squamous-like enhancer landscapes to drive oncogenic target expression during SCC development. Importantly, ΔNp63α acts as an upstream regulator of super enhancers to activate a number of oncogenic transcripts linked to poor prognosis in SCC. Mechanistically, ΔNp63α activates genes transcription through physically interacting with a number of epigenetic modulators to establish enhancers and enhance chromatin accessibility. In contrast, ΔNp63α also represses gene transcription via interacting with repressive epigenetic regulators. ΔNp63α expression is regulated at multiple levels, including transcriptional, post-transcriptional, and post-translational levels. In this review, we summarize recent advances of p63 in epigenomic and transcriptional control, as well as the mechanistic regulation of p63.
- 23 May 2020
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 77 (21) , 4325-4346
Open AccessTP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development
Squamous cell carcinoma (SCC) is an aggressive malignancy that can originate from various organs. TP63 is a master regulator that plays an essential role in epidermal differentiation. It is also a lineage-dependent oncogene in SCC. ΔNp63α is the prominent isoform of TP63 expressed in epidermal cells and SCC, and overexpression promotes SCC development through a variety of mechanisms. Recently, ΔNp63α was highlighted to act as an epidermal-specific pioneer factor that binds closed chromatin and enhances chromatin accessibility at epidermal enhancers. ΔNp63α coordinates chromatin-remodeling enzymes to orchestrate the tissue-specific enhancer landscape and three-dimensional high-order architecture of chromatin. Moreover, ΔNp63α establishes squamous-like enhancer landscapes to drive oncogenic target expression during SCC development. Importantly, ΔNp63α acts as an upstream regulator of super enhancers to activate a number of oncogenic transcripts linked to poor prognosis in SCC. Mechanistically, ΔNp63α activates genes transcription through physically interacting with a number of epigenetic modulators to establish enhancers and enhance chromatin accessibility. In contrast, ΔNp63α also represses gene transcription via interacting with repressive epigenetic regulators. ΔNp63α expression is regulated at multiple levels, including transcriptional, post-transcriptional, and post-translational levels. In this review, we summarize recent advances of p63 in epigenomic and transcriptional control, as well as the mechanistic regulation of p63.
- Open Access
- 5 December 2019
- Published by Wiley in Advanced Science
- Vol. 7 (3) , 1901380
Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer
As a transcription coactivator, Yes‐associated protein 1 (YAP1)'s role in tumorigenesis is well established. However, the mechanism of YAP1‐regulating long noncoding RNAs (lncRNA) in tumors is still largely unknown. Here, a YAP1 target gene, long intergenic noncoding RNA 00152 (LINC00152), which is highly expressed in colorectal cancer (CRC), is identified. The oncogenic functions of LINC00152 in CRC are demonstrated by a panel of in vitro and in vivo experiments. Further studies reveal the potential downstream mechanisms of LINC00152, which can act as a competing endogenous RNA sponging with miR‐632 and miR‐185‐3p to regulate Fascin actin‐bundling protein 1 (FSCN1) expression and thus promote the malignant proliferation and metastasis in CRC cells. Targeting the YAP1/LINC00152/FSCN1 axis inhibits the progression of CRC. This finding provides a new regulatory model of the “YAP1‐lncRNA” in CRC, which gives rise to a new perspective, “YAP1/LINC00152/miR‐632‐miR‐185‐3p/FSCN1,” to explore the cancer‐promoting mechanism of YAP1 involved in CRC.
- 5 December 2019
- Published by Wiley in Advanced Science
- Vol. 7 (3) , 1901380
Open AccessTargeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer
As a transcription coactivator, Yes‐associated protein 1 (YAP1)'s role in tumorigenesis is well established. However, the mechanism of YAP1‐regulating long noncoding RNAs (lncRNA) in tumors is still largely unknown. Here, a YAP1 target gene, long intergenic noncoding RNA 00152 (LINC00152), which is highly expressed in colorectal cancer (CRC), is identified. The oncogenic functions of LINC00152 in CRC are demonstrated by a panel of in vitro and in vivo experiments. Further studies reveal the potential downstream mechanisms of LINC00152, which can act as a competing endogenous RNA sponging with miR‐632 and miR‐185‐3p to regulate Fascin actin‐bundling protein 1 (FSCN1) expression and thus promote the malignant proliferation and metastasis in CRC cells. Targeting the YAP1/LINC00152/FSCN1 axis inhibits the progression of CRC. This finding provides a new regulatory model of the “YAP1‐lncRNA” in CRC, which gives rise to a new perspective, “YAP1/LINC00152/miR‐632‐miR‐185‐3p/FSCN1,” to explore the cancer‐promoting mechanism of YAP1 involved in CRC.